DiPRO1 distinctly reprograms muscle and mesenchymal cancer cells

Area of Science:

• Molecular biology
• Cancer research
• Epigenetics

Background:

• Facioscapulohumeral dystrophy involves the 4qA locus and uncharacterized proteins.
• Myogenesis is regulated by master regulators like SIX1.
• Mesenchymal tumors (RMS, Ewing sarcoma) have complex regulatory mechanisms.

Purpose of the Study:

• Identify the function of the uncharacterized ZNF555 protein.
• Elucidate DiPRO1's role in myoblast differentiation and proliferation.
• Investigate DiPRO1's involvement in mesenchymal tumor development and potential therapeutic strategies.

Main Methods:

• Protein identification and complex analysis.
• Myoblast differentiation and proliferation assays.
• Epigenetic analysis (methylation) and gene expression studies.
• In vitro cancer cell models and nanomedicine delivery systems.

Main Results:

• ZNF555, named DiPRO1, is essential for human myoblast differentiation and proliferation, interacting with SIX1.
• DiPRO1 represses mesenchymal tumors (RMS, Ewing sarcoma) by maintaining DNA methylation via TIF1B and UHRF1.
• DiPRO1 loss activates innate immune responses, including retrotransposable elements and ZNF/KZFP families.
• DiPRO1 regulates TNF-α via NF-kappaB signaling, promoting inflammation and apoptosis in cancer cells.
• Mesenchymal cancers exhibit vulnerability to DiPRO1-targeting nanomedicines.

Conclusions:

• DiPRO1 is a key regulator of myogenesis and a tumor suppressor in mesenchymal cancers.
• DiPRO1's epigenetic regulatory functions are critical for maintaining cellular homeostasis.
• Targeting DiPRO1 with nanomedicines offers a promising therapeutic avenue for mesenchymal tumors.